UniQure (QURE) Posts Q4 Loss Of US$37.1m Reinforcing Profitability Concerns

Simply Wall St.03-03 10:22

uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616339926?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-03 10:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616339926","market":"us","top_or_hot":-1,"title":"UniQure (QURE) Posts Q4 Loss Of US$37.1m Reinforcing Profitability Concerns","media":"Simply Wall St.","content":"<div>\n<p>uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-posts-q4-loss-of-us371m-reinforcing-profitabili\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UniQure (QURE) Posts Q4 Loss Of US$37.1m Reinforcing Profitability Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUniQure (QURE) Posts Q4 Loss Of US$37.1m Reinforcing Profitability Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-03 10:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-posts-q4-loss-of-us371m-reinforcing-profitabili><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-posts-q4-loss-of-us371m-reinforcing-profitabili\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-posts-q4-loss-of-us371m-reinforcing-profitabili","article_id":"2616339926","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-posts-q4-loss-of-us371m-reinforcing-profitabili","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616339926","pubTimestamp":1772504562,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over recent quarters, the company has seen revenue move between US$1.6 million and US$5.6 million while basic EPS ranged from a loss of US$0.59 to a loss of US$1.38. This gives investors a clear picture of a business that is still in heavy investment mode rather than focused on near term...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","QURE":"uniQure N.V.","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"UniQure(QURE)第四季度亏损3710万美元，加剧盈利能力担忧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":1.5},"content_text":"uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over recent quarters, the company has seen revenue move between US$1.6 million and US$5.6 million while basic EPS ranged from a loss of US$0.59 to a loss of US$1.38. This gives investors a clear picture of a business that is still in heavy investment mode rather than focused on near term profitability. With the share price around US$10.50 and margins still under pressure, the latest results put the spotlight squarely on how quickly the revenue base can scale against continued losses. See our full analysis for uniQure. With the headline numbers on the table, the next step is to see how this earnings print lines up with the big stories already priced into QURE, and where the data pushes back against the prevailing narratives. See what the community is saying about uniQure NasdaqGS:QURE Earnings & Revenue History as at Mar 2026 AdvertisementUS$199 million of losses on a US$16 million revenue base  Over the last twelve months to Q4 2025, QURE generated US$16.1 million of revenue against a net loss of US$199.0 million, so the company is still very much in spending mode to build out its gene therapy pipeline.  Bulls point to the roughly 51% forecast annual revenue growth as the key offset to these losses, but the gap is wide enough that execution has to be very strong over time.\n     Bullish views highlight AMT-130 for Huntington's disease and other programs like AMT-260 and AMT-191 as potential future revenue sources, yet current quarterly revenue between US$1.6 million and US$5.6 million shows that commercial scale is still ahead. Supporters also mention guidance that existing cash can fund operations into 2029, which gives time for those programs to advance, while the latest twelve month loss of US$199.0 million underlines how reliant the story is on that funding runway.    Bulls argue that these losses are the price of building a first mover gene therapy portfolio and that the real question is whether programs like AMT-130 can eventually justify the spend. If you want to see how that optimistic case is built out in full, check out the 🐂 uniQure Bull Case High P/S multiple with a big DCF gap  QURE trades on a P/S of 40.6x compared to 12.5x for the US biotechs industry and 26.6x for peers, while the DCF fair value cited for the company sits at about US$592.47, far above the current share price of US$10.50.  Bears focus on this mix of a very high sales multiple and a very large modelled DCF gap as a sign that expectations are already ambitious even though the business is loss making.\n     Cautious views argue that with the company still posting trailing twelve month EPS of a US$3.46 loss and net losses near US$199.0 million, it is hard to rely on long range DCF outputs without clearer progress toward positive margins. Critics also point out that valuation scenarios in the bearish narrative require very high future P/E multiples on relatively modest earnings, which lines up with the current premium P/S of 40.6x and keeps valuation risk front and center.    Skeptical investors suggest the current valuation already prices in a lot of future success. If you want to see how the more cautious case frames those risks in detail, have a look at the 🐻 uniQure Bear Case Volatile share price and dilution alongside growth forecasts  The shares have been highly volatile over the past three months, and investors were diluted over the past year, even as analysts point to around 51% forecast annual revenue growth from this small base.  The balanced, more consensus style narrative weighs that strong growth outlook against execution and funding risks that show up in the recent volatility and dilution.\n     Consensus commentary flags that QURE is expected to remain unprofitable for at least the next three years, so any new equity issuance to support a pipeline where quarterly net losses have ranged from about US$37.1 million to US$80.5 million directly affects existing holders. At the same time, the presence of several programs and a funded runway gives the company shots on goal, and recent swings in the US$10.50 share price illustrate how sensitive the stock can be to updates on trials, regulation, or financing.    Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for uniQure on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. Reading all this, you can see both enthusiasm and concern in the story, so take a moment to review the numbers yourself and form your own stance, then check out 2 key rewards and 3 important warning signs to see how those potential upsides compare with the issues on investors' minds. Explore Alternatives QURE is still posting sizeable losses of US$199.0 million on just US$16.1 million of revenue, with volatility, dilution and premium valuation metrics all weighing on confidence. If this mix of steep losses, funding reliance and price swings feels uncomfortable, you can quickly compare it with 76 resilient stocks with low risk scores that focus on more resilient profiles today.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if uniQure might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616339926","isCrawlerRequest":true}